A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

Must have received: proteasome inhibitor

previously received therapy with proteasome inhibitors and immunomodulatory drugs, and who had disease progression on prior therapy

Must have received: immunomodulatory drug

previously received therapy with proteasome inhibitors and immunomodulatory drugs, and who had disease progression on prior therapy

Cannot have received: anti-CD38 therapy (daratumumab)

Prior treatment with daratumumab or other anti-CD38 therapy.

Cannot have received: any treatment for multiple myeloma

Exception: except for a short course of glucocorticoids

Prior treatment for multiple myeloma within 2 weeks or 5 half-lives before the date of randomization, except for a short course of glucocorticoids

Cannot have received: autologous hematopoietic stem cell transplantation

Autologous hematopoietic stem cell transplantation within 12 weeks prior to the date of randomization.

Cannot have received: allogeneic hematopoietic stem cell transplantation

Allogeneic hematopoietic stem cell transplantation, regardless of timing.

Cannot have received: scheduled hematopoietic stem cell transplantation

Exception: prior to progressive disease during this study

Scheduled hematopoietic stem cell transplantation prior to progressive disease during this study.

Cannot have received: plasmapheresis

Plasmapheresis within 28 days prior to randomization.